Preliminary feasibility of pre-treatment F-18-PSMA-1007 PET/CT in dose prediction for Lu-177-PSMA-I&T therapy

Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830–45 DOI: https://doi.org/10.1007/s00259-023-06255-8

Working group set up by the Finnish Medical Society Duodecim and the Finnish Urology Association. Prostate Cancer. Current care guidelines. Helsinki: The Finnish Medical Society Duodecim; 2025 [cited 2026 Jan 28]. Available from: www.kaypahoito.fi

Castellucci P, Deandreis D, Mirzaei S, Prior J, Sattler B, Schütze C. European Nuclear Medicine Guide: a joint publication by EANM and UEMS/EBNM. European Association of Nuclear Medicine EANM, 2026 edition. Vienna. 2026.

Stabin M. The practice of internal dosimetry in nuclear medicine. 1st ed. Boca Raton, FL: CRC Press; 2016. DOI: https://doi.org/10.1201/9781315372792

Danieli R, Milano A, Gallo S, Veronese I, Lascialfari A, Indovinaet L, et al. Personalized dosimetry in targeted radiation therapy: a look to methods, tools and critical aspects. J Pers Med. 2022;12(2):205 DOI: https://doi.org/10.3390/jpm12020205

Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778–809 DOI: https://doi.org/10.1007/s00259-022-05727-7

Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [177Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis. J Nucl Med. 2024;65(8):1264–71 DOI: https://doi.org/10.2967/jnumed.124.267452

Tran-Gia J, Denis-Bacelar AM, Ferreira KM, Robinson AP, Calvert N, Fenwick AJ, et al. A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project. EJNMMI Phys. 2021;8(1):55 DOI: https://doi.org/10.1186/s40658-021-00397-0

Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, et al. Differences and common ground in 177Lu-PSMA radioligand therapy practice patterns: international survey of 95 theranostic centers. J Nucl Med. 2024;65(3):438–45 DOI: https://doi.org/10.2967/jnumed.123.266391

Dickson J, Claeys W, Denis-bacelar A, Hristova I, Lassmann M, Koole M, et al. An EANM/EARL accreditation standard for quantitative Lu-177 SPECT-CT imaging. J Nucl Med. 2025;66(Supplement 1): 251783–251783.

Dadgar H, Karimzadeh R, Sharifi S, Hong X, Al balooshi B, Arabi H, et al. Predicting post-treatment outcomes of Lu-177 PSMA therapy using deep learning on pre-treatment Ga-68 PSMA PET images. J Nucl Med. 2025;66(Supplement 1):252132– 252132.

Yazdani E, Neizehbaz A, Karamzade-Ziarati N, Emami F, Vosoughi H, Asadi M. Transforming [177Lu]Lu-PSMA-617 treatment planning: Machine learning-based radiodosiomics and swin UNETR using pretherapy PSMA positron emission tomography/computed tomography (PET/CT). Med Phys. 2025;52(10):e70030 DOI: https://doi.org/10.1002/mp.70030

Yazdani E, Sadeghi M, Karamzade-Ziarati N, Jabari P, Amini P, Vosoughi H. Machine learning-based dose prediction in [177Lu]Lu-PSMA-617 Therapy by integrating biomarkers and radiomic features from [68Ga]Ga-PSMA-11 Positron emission tomography/computed tomography. Int J Radiat Oncol Biol Phys. 2025;123(3):891–908 DOI: https://doi.org/10.1016/j.ijrobp.2025.05.014

Hohberg M, Reifegerst M, Drzezga A, Wild M, Schmidt M. Prediction of response to 177Lu-PSMA therapy based on tumor-to-kidney ratio on pretherapeutic PSMA PET/CT and posttherapeutic tumor-dose evaluation in mCRPC. J Nucl Med. 2023;64(11):1758–64 DOI: https://doi.org/10.2967/jnumed.122.264953

Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517–23 DOI: https://doi.org/10.2967/jnumed.118.219352

Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging 2017;44(Suppl 1):17–31 DOI: https://doi.org/10.1007/s00259-017-3740-2

Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13(4):601–9 DOI: https://doi.org/10.1109/42.363108

Wan H. Automated contouring using neural networks. White Paper TD-650. Cleveland, OH: MIM Software Inc.; 2024.

Nelson AD, Nelson AS. MIM for therapy response evaluation. White Paper MIMTD-486. Cleveland, OH: MIM Software Inc.; 2018.

International Atomic Energy Agency (IAEA). Quality assurance for PET and PET/CT systems. IAEA Human Health Series No. 1. Vienna: International Atomic Energy Agency; 2009.

Reijonen V, Kokkonen S, Tenhunen M. Recovery coefficients in Lu-177-SPECT-CT are reduced as a function of activity concentration. EANM Innovation. 2025;1(Suppl):44–5

Madsen MT, Menda Y, O’Dorisio TM, O’Dorisio MS. Technical note: single time point dose estimate for exponential clearance. Med Phys. 2018;45(5):2318–24 DOI: https://doi.org/10.1002/mp.12886

Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022;63(8):1199–207 DOI: https://doi.org/10.2967/jnumed.121.262713

Karimzadeh A, Schatz L, Sauer M, Apostolova I, Buchert R, Klutmann S, et al. Organ and tumor dosimetry including method simplification for [177Lu]Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer. EJNMMI Phys. 2024;11(1):63 DOI: https://doi.org/10.1186/s40658-024-00668-6

Okamoto S, Thieme A, Allmann J, D’Alessandria C, Maurer T, Retz M, et al. Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med. 2017;58(3):445–50 DOI: https://doi.org/10.2967/jnumed.116.178483

Feuerecker B, Chantadisai M, Allmann A, Tauber R, Allmann J, Steinhelfer L, et al. Pretherapeutic comparative dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2022;63(6):833–9 DOI: https://doi.org/10.2967/jnumed.121.262671

Barna S, Haug AR, Hartenbach M, Rasul S, Grubmüller B, Kramer G, et al. Dose calculations and dose-effect relationships in 177Lu-PSMA I&T radionuclide therapy for metastatic castration-resistant prostate cancer. Clin Nucl Med. 2020;45(9):661–7 DOI: https://doi.org/10.1097/RLU.0000000000003157

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57(7):1006–13 DOI: https://doi.org/10.2967/jnumed.115.168443

Hardiansyah D, Patrianesha BB, Glatting G. Population pharmacokinetic modeling in radiopharmaceutical therapy: a review. Front Nucl Med. 2025;5:1695332 DOI: https://doi.org/10.3389/fnume.2025.1695332

Peters SMB, Hofferber R, Privé BM, de Bakker M, Gotthardt M, Janssen M, et al. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49(4):1101–12 DOI: https://doi.org/10.1007/s00259-021-05538-2

Akhavanallaf A, Lu Z, Peterson AB, Blakkisrud J, Kurkowska S, Yadav S, et al. Can 177Lu-DOTATATE kidney absorbed doses be predicted from pretherapy SSTR PET? Findings from multicenter data. J Nucl Med. 2025;66(7):1082–90 DOI: https://doi.org/10.2967/jnumed.124.269098

Capasso G, Stefanucci A, Tolomeo A. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy. Eur J Med Chem. 2024;263:115966 DOI: https://doi.org/10.1016/j.ejmech.2023.115966

Kabasakal L, AbuQbeitah M, Aygün A,Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(13):1976–83 DOI: https://doi.org/10.1007/s00259-015-3125-3

Privé BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, et al. 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. Eur J Nucl Med Mol Imaging. 2022;49(6):2064–76 DOI: https://doi.org/10.1007/s00259-021-05661-0